Pharmacotherapeutic Management of Nicotine Dependence in Pregnancy

Obstetrics and Gynecology Clinics of North America

Volumn 38, Issue 2, 2011, Pages 297-311

  Clark, Shannon M ^a   Nakad, Ramzy ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Management; Nicotine dependence; Pregnancy; Smoking

Indexed keywords

AMFEBUTAMONE; COTININE; DOPAMINE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; PLACEBO; VARENICLINE;

ABNORMAL DREAMING; AGITATION; BEHAVIOR CHANGE; BIRTH DEFECT; CONSTIPATION; DEPRESSION; DOPAMINE RELEASE; DRUG ACTIVITY; DRUG CLASSIFICATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; ERYTHEMA MULTIFORME; FETUS RISK; FLATULENCE; GASTROINTESTINAL DISEASE; HUMAN; INSOMNIA; KIDNEY CLEARANCE; LOW DRUG DOSE; MENTAL DISEASE; MOOD CHANGE; NAUSEA; NICOTINE REPLACEMENT THERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN IRRITATION; SLEEP DISORDER; SMOKING CESSATION; SUICIDAL IDEATION; SUSTAINED RELEASE FORMULATION; TERATOGENICITY; TOBACCO DEPENDENCE; TREATMENT CONTRAINDICATION; TREATMENT DURATION; WITHDRAWAL SYNDROME; XEROSTOMIA;

FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER; TRANSDERMAL PATCH;

EID: 79955963581     PISSN: 08898545     EISSN: 15580474     Source Type: Journal    
DOI: 10.1016/j.ogc.2011.02.017     Document Type: Review

References (84)

1. The Surgeon General's 1990 Report on The Health Benefits of Smoking Cessation. Executive Summary. Anonymous Morbidity & Mortality Weekly Report Recommendations & Reports 1990;39(RR-12):i-xv, 1-12. Available at: Accessed February 28, 2011. http://ovidsp.tx.ovid.com/sp-3.3.1a/ovidweb.cgi%3f%26S%3dJNPAFPBNPLDDJGFANCCLNEMCHPECAA00&Complete+Reference=S.sh.14%7c4%7c1.
2. Fang W.L., Goldstein A.O., Butzen A.Y., et al. Smoking cessation in pregnancy: a review of postpartum relapse prevention strategies. J Am Board Fam Pract 2004, 17(4):264-275.
3. U.S.Department of Health and Human Services Women and smoking: a report of the Surgeon General 2001, vol. 17. U.S. Department of Health and Human Services, Public Health Service, Office of the Surgeon General, Rockville (MD), 2002. p. 264-75.
4. Lumley J., Oliver S.S., Chamberlain C., et al. Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev 2004, 4. CD001055.
5. Centers for Disease Control and Prevention (CDC) Medical care expenditures attributable to cigarette smoking during pregnancy-United States. MMWR Morb Mortal Wkly Rep 1997, 46(44):1048-1050.
6. Brown H.L., Hopf S.K. Clinical perspectives on smoking during pregnancy. Female Patient 1998, 23:59.
7. Crawford J.T., Tolosa J.E., Goldenberg R.L. Smoking cessation in pregnancy: why, how, and what next. Clin Obstet Gynecol 2008, 51:419-435.
8. Raymond E.G., Cnattingius S., Kiely J.L. Effects of maternal age, parity, and smoking on the risk of stillbirth. Br J Obstet Gynaecol 1994, 101(4):301-306.
9. Higgins S. Smoking in pregnancy. Curr Opin Obstet Gynecol 2002, 14:145-151.
10. Lumley J., Oliver S., Waters E. Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev 2000, 2. (Cochrane Review) (1999), CD001055. Update Software, Oxford (UK).
11. CDC Trends in smoking before, during, and after pregnancy-Pregnancy Risk Assessment Monitoring System (PRAMS) 2009, United States, 31 sites, 2000-2005. Surveillance summaries. MMWR Morb Mortal Wkly Rep 2009, 58:1-36.
12. Larsen L.G., Clausen H.V., Jonsson L. Stereologic examination of placentas from mothers who smoke during pregnancy. Am J Obstet Gynecol 2002, 186:531-537.
13. Lehtovirta P., Forss M. The acute effect of smoking on intervillous blood flow of the placenta. Br J Obstet Gynaecol 1978, 85:729.
14. Benowitz N.L., Gourlay S.G. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol 1997, 29:1422-1431.
15. Maritz G.S. Are nicotine replacement therapy, varenicline or bupropion options for pregnant mothers to quit smoking? Effects on the respiratory system of the offspring. Ther Adv Respir Dis 2009, 3:193-210.
16. Andres R.L., Day M.C. Perinatal complications associated with maternal tobacco use. Semin Neonatol 2000, 5:231-241.
17. Benowitz N.L., Dempsey D.A. Pharmacotherapy for smoking cessation during pregnancy. Nicotine Tob Res 2004, 6(Suppl 2):S189-S202.
18. Sekhon H.S., Jia Y., Raab R., et al. Prenatal nicotine increases pulmonary alpha7 nicotinic receptor expression and alters fetal lung development in monkeys. J Clin Invest 1999, 103:637-647.
19. Sekhon H.S., Keller J.A., Benowitz N.L., et al. Prenatal nicotine exposure alters pulmonary function in newborn rhesus monkeys. Am J Respir Crit Care Med 2001, 164(6):989-994.
20. Slotkin T.A., Cho H., Whitmore W.L. Effects of prenatal nicotine exposure on neuronal development: selective actions on central and peripheral catecholaminergic pathways. Brain Res Bull 1987, 18:601-611.
21. Dempsey D.A., Benowitz N.L. Risks and benefits of nicotine to aid smoking cessation in pregnancy. Drug Saf 2001, 24:277-322.
22. Tomkins D.M., Sellers E.M. Addiction and the brain: the role of neurotransmitters in the cause and treatment of drug dependence. CMAJ 2001, 4:817-821.
23. Pontieri F.E., Tanda G., Orzi G., et al. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996, 382(6588):255-257.
24. Mas R., Escriba V., Colomer C. Who quits smoking during pregnancy?. Scand J Soc Med 1996, 24:102-106.
25. Lumely J. Stopping smoking. Br J Obstet Gynaecol 1987, 94:289-292.
26. Coleman T. Special groups of smokers. BMJ 2005, 328:575-577.
27. U.S.Department of Health and Human Services Clinical Practice Guideline. Treating tobacco use and dependence: 2008 update 2008, U.S. Department of Health and Human Services, Public Health Service, Office of the Surgeon General, Rockville (MD).
28. Li C.Q., Windsor R.A., Perkins L., et al. The impact on infant birth weight and gestational age of cotinine-validated smoking reduction during pregnancy. JAMA 1993, 269:1519-1524.
29. Dolan-Mullen P., Ramirez G., Groff J.Y. A meta-analysis of randomized trials of prenatal smoking cessation interventions. Am J Obstet Gynecol 1994, 171:1328-1334.
30. Lancaster T., Stead L.F. Physician advice for smoking cessation. Cochrane Database of Systematic Reviews 2004, 4:CD000165.
31. Benowitz N.L., Dempsey D.A., Goldenberg R.L., et al. The use of pharmacotherapies for smoking cessation during pregnancy. Tob Control 2000, 9:iii91-iii94.
32. Rigotti N.A., Park E.R., Chang Y., et al. Smoking cessation medication use among pregnant and postpartum smokers. Obstet Gynecol 2008, 111:348-355.
33. Oncken C.A., Kranzler H.R. What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy?. Nicotine Tob Res 2009, 11(11):1265-1273.
34. Hudmon K.S., Corelli R.L., Prokhorov A.V. Current approaches to pharmacotherapy for smoking cessation. Ther Adv Respir Dis 2010, 4:35-47.
35. Benowitz N.L. Nicotine replacement therapy during pregnancy. JAMA 1991, 266(22):3174-3177.
36. ACOG committee opinion Smoking cessation during pregnancy. ACOG Committee on Health Care for Underdeserved Women. ACOG Committee on Obstetric Practice. Obstetrics & Gynecology 2005, 106(4):883-888. Available at:, Accessed February 28, 2011. http://ovidsp.tx.ovid.com/sp-3.3.1a/ovidweb.cgi%3f%26S%3dJNPAFPBNPLDDJGFANCCLNEMCHPECAA00&Link+Set=S.sh.57%7c1%7csl_10.
37. Oncken C.A., Hatsukami D.K., Lupo V.R., et al. Effects of short-term use of nicotine gum in pregnant smokers. Clin Pharmacol Ther 1996, 59:654-661.
38. Ogburn P.L., Hurt R.D., Croghan I.T., et al. Nicotine patch use in pregnant smokers: nicotine and cotinine levels and fetal effects. Am J Obstet Gynecol 1999, 181:736-743.
39. Coleman T., Britton J., Thornton J. Nicotine replacement therapy in pregnancy. BMJ 2004, 328:965-966.
40. Herbert R., Coleman T., Britton J. UK general practitioners' beliefs, attitudes, and reported prescribing of nicotine replacement therapy in pregnancy. Nicotine Tob Res 2005, 7:541-546.
41. Price J.H., Jordan T.R., Drake J.A. Obstetricians and gynecologists' perceptions and use of nicotine replacement therapy. J Community Health 2006, 31:160-175.
42. Oncken C.A., Pbert L., Ockene J.L., et al. Nicotine replacement prescription practices of obstetric and pediatric clinicians. Obstet Gynecol 2000, 96:261-265.
43. Molyneaux A. Nicotine replacement therapy. BMJ 2004, 328:454-456.
44. Fiore M.C., Smith S.S., Jorenby D.E., et al. The effectiveness of the nicotine patch for smoking cessation. JAMA 1994, 271:1940-1947.
45. Hajek P., West R., Foulds J., et al. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 1999, 159:2033-2038.
46. Fiore M.C., Novotny T.E., Pierce J.P., et al. Methods used to quit smoking in the United States. JAMA 1990, 263:3244-3254.
47. Hughes J.R., Stead L.F., Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007, 1. CD000031.
48. Stead L.F., Perera R., Bullen C., et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008, 1. CD000146.
49. Silagy C., Mant D., Fowler F., et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2000, 3:CD000146.
50. Miller N., Frieden T.R., Liu S.Y., et al. Effectiveness of a large-scale distribution programme of free nicotine patches: a prospective evaluation. Lancet 2005, 365:1843-1854.
51. Dempsey D., Jacob P., Benowitz N.L. Accelerated metabolism of nicotine and cotinine in pregnant smokers. J Pharmacol Exp Ther 2002, 301:594-598.
52. Wisborg K., Henrikson T.B., Jespersen L.B., et al. Nicotine patches for pregnant smokers: a randomized controlled study. Obstet Gynecol 2000, 96:967-971.
53. Galanti L.M. Tobacco smoking cessation management: integrating varenicline in current practice. Vasc Health Risk Manag 2008, 4:837-845.
54. Rayburn W.F., Bogenschutz M.P. Pharmacotherapy for pregnant women with addictions. Am J Obstet Gynecol 2004, 191:1885-1897.
55. Ferris R.M., Cooper B.R., Maxwell R.A. Studies of bupropion's mechanism of antidepressant activity. J Clin Psychiatry 1983, 44:74-78.
56. Ascher J.A., Cole J.O., Colin J.N., et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995, 56:395-401.
57. Slemmer J.E., Martin B.R., Damaj M.I. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000, 295:321-327.
58. Fiore M.C., Jaen C.R., Baker T.B., et al. Treating tobacco use and dependence: 2008 update US public health service practice guideline executive summary. Respir Care 2008, 55:1217-1222.
59. Jorenby D.E., Leishow S.J., Nides M.A., et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999, 340:685-691.
60. Hurt R.D., Sachs D.P.L., Glover E.D., et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997, 337:1195-1202.
61. Hughes J., Stead L., Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2000, 4. CD000031.
62. Goldstein M.G. Bupropion sustained release and smoking cessation. J Clin Psychiatry 1998, 56:68-72.
63. GlaxoSmithKline The bupropion pregnancy registry: final report, 1 September 1997 through 31 March 2008 Available at:, Accessed February 28, 2011. http://pregnancyregistry.gsk.com/documents/bup_report_final_2008.pdf.
64. Chun-Fai-Chan B., Koren G., Fayez I., et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 2005, 192:932-936.
65. Cole J.A., Modell J.G., Haight B.R., et al. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007, 16:474-484.
66. Alwan S., Reefhuis J., Botto L.D., et al. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol 2010, 203. 52, e1-6.
67. Hays J.T., Ebbert J.O. Bupropion sustained release for treatment of tobacco dependence. Mayo Clin Proc 2003, 78:1020-1024.
68. Hays J.T., Hurt R.D., Rigotti N.A., et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation: a randomized, controlled trial. Ann Intern Med 2001, 135:423-433.
69. Holm K., Spencer C. Bupropion: a review of its use in the management of smoking cessation. Drugs 2003, 59:1007-1024.
70. Peloso P.M., Baillie C. Serum sickness-like reaction with bupropion. JAMA 1999, 282:1817. [letter].
71. Lineberry T.W., Peters G.E., Bostwick J.M. Bupropion-induced erythema multiforme. Mayo Clin Proc 2001, 76:664-666.
72. Crunelle C.L., Miller M.L., Booij J., et al. The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review. Eur Neuropsychopharmacol 2010, 20:69-79.
73. Coe J.W., Brooks P.R., Vetelino M.G., et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005, 48:3474-3477.
74. Cahill K., Stead L., Lancaster T. A preliminary benefit-risk assessment of varenicline in smoking cessation. Drug Saf 2009, 32:119-135.
75. Rao J., Shankar P.K. Varenicline: for smoking cessation. Kathmandu Univ Med J (KUMJ) 2009, 7:162-164.
76. Foulds J. The neurobiological basis for partial agonist treatment of nicotinic dependence: varenicline. Int J Clin Pract 2006, 60:571-576.
77. Coleman T. Recommendations for the use of pharmacological smoking cessation strategies in pregnant women. CNS Drugs 2007, 21:983-993.
78. Tonstad S., Rollema H. Varenicline in smoking cessation. Expert Rev Respir Med 2010, 4(3):291-299. Health Reference Center Academic. Wed. 18 Oct 2010.
79. Jorenby D.E., Taylor H., Rigotti N.A., et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. JAMA 2006, 296:56-63.
80. Gonzales D., Rennard S.I., Nides M., et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained release bupropion for smoking cessation. JAMA 2006, 296(1):47-55.
81. Aubin H.-J., Bobak A., Britton J.R., et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomized open-label trial. Thorax 2008, 63:717-724.
82. Hays J.T., Ebbert J.O. Varenicline for tobacco dependence. N Engl J Med 2008, 359:20182024.
83. Keating F.M., Leyseng-Williamson K.A. Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation. Pharmacoeconomics 2010, 28:231-254.
84. Center for Drug Evaluation and Research Varenicline (marketed as Chantix) information: FDA alert 2008, food and Drug Administration, Rockville (MD).